Terkko Navigator / Current Opinion in Pulmonary Medicine

Editorial introductions.

Pulmonary hypertension in majority countries: opportunities amidst challenges.

How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium.

Clinical trials in group 3 pulmonary hypertension.

Advanced therapies for pulmonary embolism.

Evolving spectrum of treatment for CTEPH.

Critical care of patients with pulmonary arterial hypertension.

Pulmonary arterial hypertension: closing the gap in congenital heart disease.

Pathogenesis of fibrosis in interstitial lung disease.

Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.

Obstructive sleep apnea in pulmonary fibrosis.

Frailty in patients with interstitial lung disease.

Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.

Oxygen for interstitial lung diseases.

Pulmonary rehabilitation in interstitial lung diseases.

Recent advances in rheumatoid arthritis-associated interstitial lung disease.

Systemic sclerosis-associated interstitial lung disease.

New therapeutic strategies in lung vasculitis.

Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases.

Advances in lung transplantation for interstitial lung diseases.

The future is now: a generation of sarcoidologists emerges.

Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors.

Immunology of sarcoidosis: old companions, new relationships.

Recent advances in sarcoidosis genomics: epigenetics, gene expression, and gene by environment (G x E) interaction studies.

Experimental models of sarcoidosis: where are we now?.

Molecular profiling in sarcoidosis.

Socioeconomic determinants and disparities in sarcoidosis.

Advanced pulmonary sarcoidosis.

An update on sarcoidosis-associated pulmonary hypertension.

Current treatment of sarcoidosis.

Looking into the future of sarcoidosis: what is next for treatment?.

Editorial introductions.

Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options?.

A contemporary review of radiation pneumonitis.

Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.

Management of malignant pleural effusions.

What's new in endobronchial ultrasound for mediastinal staging?.

Interaction of diet and drugs in lung disease.

Role of antioxidants in the treatment of gastroesophageal reflux disease-associated idiopathic pulmonary fibrosis.

Editorial introductions.

Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security.

Transmission of respiratory tract infections at mass gathering events.

Update in adult community-acquired pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline.

Viral respiratory infections: a cause of community-acquired pneumonia or a predisposing factor?.

Influenza management with new therapies.

Pneumococcal virulence factors in community-acquired pneumonia.

New biomarkers for respiratory infections.

Advances in molecular diagnostic tests for pneumonia.

Strategies for prediction of drug-resistant pathogens and empiric antibiotic selection in community-acquired pneumonia.

Beyond antibiotics for pulmonary nontuberculous mycobacterial disease.